Tenured Professor | Co-Director, Hanna & Mark Gleiberman Center | Vice Chair, Clinical & Translational Research | UC San Diego Dept. of Radiation Medicine
San Diego, CA
Joined August 2011
- Tweets524
- Following861
- Followers1.1K
- Likes765
Dr. Loren K. Mell retweeted
We join the oncology community in mourning the passing of Dr. Rachna T. Shroff, a renowned GI cancers expert and a dedicated ASCO volunteer. We are humbled by her dedication and strive to honor her legacy of commitment and altruism.
Read more: bit.ly/4e7jBKu
Dr. Loren K. Mell retweeted
Thank you for the incredible mentorship 🎉 looking forward to continuing our search for answers @TylerSbrt
So proud of @adornisch_MD, the resident I started this conversation with, now faculty @UCSDRadMed. Absolute superstar! So excited to watch her career 💫❤️
Dr. Loren K. Mell retweeted
THURSDAY we're looking at the CONCISE study (NRG-HN016) in cisplatin-ineligible locoregionally advanced head and neck cancer with Study PI @drlorenmell - Follow our podcast and stream episodes directly from NRGOncology.org/Podcast
Dr. Loren K. Mell retweeted
Tune in on August 13th while we discuss the CONCISE study (NRG-HN016) in cisplatin-ineligible locoregionally advanced head and neck cancer with Study PI @drlorenmell - Follow our podcast and stream episodes directly from NRGOncology.org/Podcast
Dr. Loren K. Mell retweeted
It’s been a while but feel I should share what may be my greatest accomplishment to date. Grew these beets in my garden #enormous #dwightshrute 🤷🏻♀️Size of a large watermelon, cork pictured for reference #organicgardening
Dr. Loren K. Mell retweeted
Congratulations to @jmmrad on being awarded Fellow membership in @aapmHQ. Jeff has been a tireless advocate for the entire field of rad onc throughout his long and distinguished career.
Congratulations Jeff!
@ASTRO_org #radonc @RadiologyACR @ABR_Radiology @ACRORadOnc @ASCO
Happy to share my first published poem! 😀 This link should be active until Aug 13 : authors.elsevier.com/a/1nK8d…
Dr. Loren K. Mell retweeted
We are simplifying how NIH funding works so researchers can spend less time navigating complexity and more time on discovery.
Stay informed with @NIH_Innovates, NIH’s new channel dedicated to research news and information for the biomedical research community.
Dr. Loren K. Mell retweeted
Join us in Denver, Colorado for the #NRG2026 Summer Meeting. The meeting will be held in-person, July 16-18, 2026, with select virtual sessions being held July 10-17, 2026. Register soon to avoid the late registration fee! ow.ly/C6ZU50ZbYxp
Dr. Loren K. Mell retweeted
Protocol Activation! NRG-HN016: Radiotherapy with Concurrent Cetuximab vs. Carboplatin & Paclitaxel in Patients with Locoregionally Advanced Head & Neck Cancer with a Contraindication to Cisplatin: A Pragmatic Phase III Randomized Trial (CONCISE).
@drlorenmell
Dr. Loren K. Mell retweeted
#ASCO26
Eager to review the Ph2 #KEYCHAIN presentation about patients with unfavorable-risk p16+ HNSCC
Thought-provoking trial in this difficult space to reach a H&N PACIFIC/ADRIATIC protocol as in lung. Unlike KN412, pembro is replacing cis, not added to CRT
Radical RT+pembro vs RT+Cis
📈2yPFS: 84vs70%; HR 0.57 (0.25-1.31) p=0.09 🟢
📈2yOS: 98vs85%; HR 0.33 (0.09-1.28) p=0.048🟢
⚠️lenient 1-side α=0.15
June 1. HallD1. 4:30. @drlorenmell #hncsm @OncoAlert @brunolarvol
Dr. Loren K. Mell retweeted
Our letter to the editor in The Lancet critiquing the MD Anderson-led trial of protons v photons for OPC. Appreciate @SJFrankMD's well thought out response.
I think we can all agree on two points:
1) Steve deserves major kudos for bringing level 1 evidence to the debate on protons v photons for OPC. These trials are extraordinarily difficult to run, and Steve, et al pulled it off. Well done!
2) Longer term follow-up from TORPEdO will help tease out the extent to which protons improves OS in OPC.
@CJTsaiMDPhD @drlorenmell @xrtGenomics @DavidSherMD #radonc #hncsm
thelancet.com/journals/lance…
Dr. Loren K. Mell retweeted
NRG-HN016 CONCISE is a pragmatic Phase 3 trial for cisplatin-ineligible locoregionally advanced #headandneckcancer. It is anticipated to be activating soon. Study PI, Dr. Loren Mell @drlorenmell describes the design of the trial in our April newsletter: ow.ly/Bt0250YIZos
Dr. Loren K. Mell retweeted
👋👋👋 Congrats to the investigators for the long awaited publication of this well-executed trial.
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, ran... sciencedirect.com/science/ar…
@seanmmcbride @DavidSherMD @KaramLab
Dr. Loren K. Mell retweeted
The ideal day in medicine without specialists:
9am: perform an EBUS
10am: knee replacement
12pm: admit a patient with acute hyponatremia
1pm: cardiac cath on a STEMI → triple vessel disease → convert to CABG
3pm: read a blood film for schistocytes
5pm: deliver a baby
Dr. Loren K. Mell retweeted
Shooting quarks into tumors is a unique quirk of the Florida medical landscape
Mayo Clinic’s doctors and researchers are on the front lines of Florida’s fight against cancer. Today, we were happy to announce that Mayo Clinic in Jacksonville will be launching the first carbon ion therapy program in America.
Carbon ion therapy, one of the most advanced forms of radiation treatment in the world, is designed to attack some of the most aggressive and treatment-resistant cancers. This cutting-edge treatment has the potential to save lives and give hope to those who need it most. Proton therapy will also be available in the same facility, allowing specialists to treat tumors with a higher degree of precision.
While carbon ion therapy was originally discovered in the United States decades ago, it has only been available at a limited number of centers in Asia and Europe until now. Soon, cancer patients will have access to therapies that previously required traveling across the world, right here in Florida.
Dr. Loren K. Mell retweeted
The editors at JAMA Internal Medicine have long opposed screening and appear eager to promote reports that perpetuate radiophobia, even rejecting letters to the editor that point out flaws in such reports. As a result, JAMA Internal Medicine has lost credibility as a reliable source for studies on early detection.
Fortunately, the main JAMA journal continues to excel in this area and has preserved its historical scientific integrity.